

# Transparency Advisory Group

## November 15, 2016

# Welcome and Introductions



# **Final Report out on Goals for 2016**



## Goal #1

TAG to approve a process by March 30, 2016 for office based medical provider data review and feedback for anticipated publication of quality data to be published starting Summer 2016.

**Goal #1 Status:**

**Completed see Open Data site**



## Goal #2

Ensure the dissemination of maternity data by facility to public facing entities that can use the data to inform care decisions by June 30, 2016.

**Goal #2 Status:**

**UtahHealthScape Go Live November 18<sup>th</sup>**



## Goal #3

Ensure 6 key groups are aware of and actively soliciting use of APCD data; we are seeing more data requests and assessing gaps in the utility to these groups: Payers, Researchers, Employers, Providers, Quality Improvement entities, and Public Health.

### **Goal #3 Status:**

**Report on Purchasers of the APCD data, also Showcase  
December 15<sup>th</sup>**



## Goal #4

Advance the breadth of Utah APCD submission data , adding uninsured patient data with FQHC pilot clinics and UHIN as well as successful advancement of Medicare Data in the APCD: evaluate all options for accessing Medicare A & B data and developing a plan to make that information available to users of the APCD by December 31,2016.

### **Goal #4 Status:**

**Qualified Entity success and AUCH HIE Pilot Data progress**



## Goal #5

TAG to review and develop use cases for dental data for patient information on dental prices for common procedures for insured patients by December 31, 2016

**Goal #5 Status:**  
**Dental Data Report**





## Goal #6

TAG to inform the use of APCD data on public health strategies on controlled substance overprescribing and harm by August 30, 2016.

### **Goal #6 Status:**

**Update on Use of APCD and CSD Data for Public Health Strategies**



# APCD Quality Measures

Measures for Comparison Reporting in 2016-2017



UTAH DEPARTMENT OF  
**HEALTH**  
Office of Health Care Statistics



## Ranked Top 5

1. Medication Management for People with Asthma (NQF 1799)
2. Comprehensive Diabetes Care: Medical Attention for Nephropathy (NQF 0062)
3. Well-Child Visits in the First 15 Months of Life (NQF 1392)
4. Use of Imaging Studies for Lower Back Pain (NQF 0052)
5. Breast Cancer Screening (NQF 2372)

# Additional Quality Measures

## Use of Imaging Studies for Lower Back Pain (NQF 0052)

The percentage of members with a primary diagnosis of low back pain who did not have an imaging study (plain x-ray, MRI, CT scan) within 28 days of the diagnosis.

## Comprehensive Diabetes Care: Medical Attention for Nephropathy (NQF 0062)

The percentage of patients 18-75 years of age with diabetes (type 1 and type 2) who received a nephropathy screening or monitoring test or had evidence of nephropathy during the measurement year.

## Well-Child Visits in the First 15 Months of Life (NQF 1392)

The percentage of children 15 months old who had the recommended number of well-child visits with a PCP during their first 15 months of life.

# Additional Quality Measures

## Medication Management for People with Asthma (MMA) (NQF 1799)

The percentage of patients 5-64 years of age during the measurement year who were identified as having persistent asthma and were dispensed appropriate medications that they remained on during the treatment period. Two rates are reported.

1. The percentage of patients who remained on an asthma controller medication for at least 50% of their treatment period.
2. The percentage of patients who remained on an asthma controller medication for at least 75% of their treatment period.

## Breast Cancer Screening (NQF 2372)

The percentage of women 50-74 years of age who had a mammogram to screen for breast cancer.

**December 15th APCD Showcase at  
HealthInsight in lieu of December TAG**



# 2017 Goals for TAG

# Wrap Up & Next Steps